Liu Jiayi, Chen Taili, Yang Haitao, Cai Yeyu, Yu Qizhi, Chen Juan, Chen Zhu, Shang Quan-Liang, Ma Cong, Chen Xiangyu, Xiao Enhua
Department of Radiology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, China.
Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410011, Hunan Province, China.
Eur Radiol. 2020 Oct;30(10):5702-5708. doi: 10.1007/s00330-020-06916-4. Epub 2020 May 8.
To analyse clinical and radiological changes from disease onset to exacerbation in coronavirus infectious disease-19 (COVID-19) patients.
We reviewed clinical histories of 276 patients with confirmed COVID-19 pneumonia and extracted data on patients who met the diagnostic criteria for COVID-19 severe/fatal pneumonia and had an acute exacerbation starting with mild or common pneumonia.
Twenty-four patients were included. Of these, 8% were smokers, 54% had been to Wuhan, and 46% had comorbidities. Before acute exacerbation, elevated lactate dehydrogenase (232.9 ± 88.7) was present, and chest CT scans showed the number of involved lobes was 4 (2-5) and total CT score was 6 (2-8). Following acute exacerbation, patients were likely to have more clinical symptoms (p < 0.01) and abnormal laboratory changes (p < 0.01). The number of involved lobes and CT score after an exacerbation significantly increased to 5 (5-5) and 12 (9-14), respectively. Receiver operating characteristic (ROC) curve showed that, when the cutoff value of CT score was 5, the sensitivity and specificity for severe pneumonia were 90% and 70%, respectively. CT findings of ground glass opacity with consolidations (91.7%), bilateral distribution (100.0%), and multifocal lesion (100.0%) were features in found in patients after exacerbation.
There are significant changes in clinical, laboratory, and CT findings in patients from disease onset to exacerbation. An increase in the number of involved lobes or an increased CT score from the baseline may predict poor clinical outcomes. Combining an assessment of CT changes with clinical and laboratory changes could help clinical teams evaluate the prognosis.
• The common chest CT signs of COVID-19 pneumonia after exacerbation were ground glass opacity (GGO) with consolidation, bilateral distribution, and multifocal lesions. • An increase in number of involved lobes or an increased CT score from the baseline may predict a poor clinical outcome. • Worsened symptoms and abnormal laboratory results are also associated with poor prognosis.
分析新型冠状病毒感染的肺炎(COVID-19)患者从发病到病情加重的临床和影像学变化。
我们回顾了276例确诊为COVID-19肺炎患者的临床病史,并提取了符合COVID-19重型/危重型肺炎诊断标准且从轻型或普通型肺炎开始急性加重的患者的数据。
纳入24例患者。其中,8%为吸烟者,54%去过武汉,46%有合并症。急性加重前,乳酸脱氢酶升高(232.9±88.7),胸部CT扫描显示受累肺叶数为4(2-5)个,总CT评分为6(2-8)分。急性加重后,患者更易出现更多临床症状(p<0.01)和实验室检查异常(p<0.01)。加重后受累肺叶数和CT评分分别显著增加至5(5-5)个和12(9-14)分。受试者工作特征(ROC)曲线显示,当CT评分临界值为5分时,重症肺炎的敏感性和特异性分别为90%和70%。加重后患者的CT表现为磨玻璃影伴实变(91.7%)、双侧分布(100.0%)和多灶性病变(100.0%)。
患者从发病到病情加重,临床、实验室检查和CT表现均有显著变化。受累肺叶数增加或CT评分较基线升高可能预示临床预后不良。结合CT变化评估与临床和实验室检查变化有助于临床团队评估预后。
• COVID-19肺炎加重后的常见胸部CT征象为磨玻璃影(GGO)伴实变、双侧分布和多灶性病变。• 受累肺叶数增加或CT评分较基线升高可能预示临床预后不良。• 症状加重和实验室检查结果异常也与预后不良有关。